Monoclonal Antibodies Market Size, Share & Trends, Growth and Forecast
monoclonal antibodies market is experiencing a surge, driven by a confluence of factors including the rising prevalence of chronic diseases
VANCOUVER, BRITISH COLUMBIA, CANADA, July 1, 2024 /EINPresswire.com/ -- The global monoclonal antibodies market is experiencing a surge, driven by a confluence of factors including the rising prevalence of chronic diseases, advancements in biotechnology, and an increasing focus on targeted therapies. According to Emergen Research, the market size was valued at a staggering $204.42 billion in 2022 and is projected to reach a phenomenal $572.62 billion by 2032, reflecting a robust compound annual growth rate (CAGR) of 10.8%.
Market Overview
Monoclonal antibodies (mAbs) are laboratory-created proteins that mimic the immune system's ability to fight off disease. They offer a highly targeted approach to treatment, minimizing side effects compared to traditional therapies. mAbs are revolutionizing various therapeutic areas, including oncology, immunology, and infectious diseases.
Get Free Sample PDF Copy Of This Report At https://www.emergenresearch.com/request-sample/2533
Key Trends Shaping the Market
Rising Prevalence of Chronic Diseases: The global burden of chronic diseases like cancer, autoimmune disorders, and neurodegenerative diseases is escalating. This surge in demand for effective treatments is propelling the mAbs market.
Technological Advancements: Breakthroughs in genetic engineering and bioprocessing are enabling the development of more potent and specific mAbs. This continuous innovation is fostering market expansion.
Growing Adoption of Biosimilars: The emergence of biosimilars, which are highly similar to existing mAbs but more affordable, is increasing access to these life-saving therapies and contributing to market growth.
Market Drivers vs. Restraints
Drivers:
Increasing government funding for research and development of mAbs
Growing geriatric population susceptible to chronic diseases
Rising healthcare expenditure and insurance coverage for biologics
Restraints:
High cost of mAb development and manufacturing
Stringent regulatory requirements for approval
Potential for patent infringement disputes
Growth Opportunities
Expansion into emerging markets like Asia Pacific
Development of mAbs for new therapeutic areas like gene therapy
Technological advancements in manufacturing to reduce production costs
Market Insights
North America currently holds the dominant market share due to advanced healthcare infrastructure and a high prevalence of chronic diseases. However, the Asia Pacific region is expected to witness the fastest growth rate owing to increasing disposable incomes and government initiatives promoting biopharmaceutical research.
The human source segment holds the largest market share due to established efficacy and safety profiles. However, the humanized mAbs segment is anticipated to grow at a significant CAGR due to their lower immunogenicity (risk of triggering an immune response).
Hospitals are the primary end-users of mAbs, but the growing adoption of home-based therapies is expected to create opportunities for the ambulatory care segment.
Ask For Customization: https://www.emergenresearch.com/request-for-customization/2533
SWOT Analysis
Strengths:
High efficacy and specificity of mAbs
Growing demand for targeted therapies
Increasing investments in R&D
Weaknesses:
High cost of development and manufacturing
Limited production capacity
Complex regulatory approval process
Opportunities:
Expansion into new markets and therapeutic areas
Technological advancements to reduce production costs
Development of biosimilars to improve affordability
Threats:
Patent expirations and competition from biosimilars
Stringent regulatory requirements
Potential for safety concerns associated with mAbs
Latest Strategic Developments
On 27 May 2021, Novartis AG, a leading pharmaceutical manufacturer, and Sub-Atomic Accomplices, a clinical-stage biopharmaceutical organization, declared the beginning of the clinical trial Eympathy, a Stage 2 and 3 study, to investigate the utilization of its original DARP in therapeutic candidate ensovibep (MP0420) for the treatment of Coronavirus.
On 10 January 2021, Sanofi, a global drug, and medical organization, declared the acquisition of Kymab, a clinical-stage biopharmaceutical organization to add KY1005, a human monoclonal antibody targeting key immune system regulator OX40L, to its pipeline.
Monoclonal Antibodies Top Companies and Competitive Landscape
The global monoclonal antibodies market is fairly fragmented, with many large and medium-sized players accounting for the majority of market revenue. Major players are deploying various strategies, entering mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing more effective monoclonal antibodies solutions.
Some major players included in the global monoclonal antibodies market report are:
Novartis AG
Pfizer Inc.
GlaxoSmithKline Plc.
Amgen Inc.
Merck & Co., Inc.
Daiichi Sankyo Company, Limited
Abbott Laboratories
AstraZeneca Plc
Eli Lilly and Company
Johnson & Johnson Services, Inc.
Bayer AG
Bristol Myers Squibb
Hoffman-La Roche Ltd.
Viatris Inc.
Biogen Inc.
Thermo Fisher Scientific, Inc.
Novo Nordisk A/S
Sanofi S.A.
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Monoclonal Antibodies Market Segment Analysis
For the purpose of this report, Emergen Research has segmented the global monoclonal antibodies market on the basis of source, indication, production type, end-use, and region:
Source Outlook (Revenue, USD Billion; 2019-2032)
Humanized mAb
Human mAb
Murine mAb
Chimeric mAb
Indication Outlook (Revenue, USD Billion; 2019-2032)
Cancer
Breast cancer
Colorectal cancer
Lung cancer
Ovarian cancer
Others
Autoimmune Diseases
Inflammatory Diseases
Infectious Diseases
Others
Production Type Outlook (Revenue, USD Billion; 2019-2032)
In Vivo
In Vitro
Distribution Channel Outlook (Revenue, USD Billion; 2019-2032)
Hospitals
Ambulatory centers
Outpatient Facilities
Others
We Have Recent Updates in Sample Copy: https://www.emergenresearch.com/request-sample/2533
Country scope: U.S., Canada, Mexico, Germany, U.K., France, Spain, BENELUX, Rest of Europe, China, India, Japan, South Korea, Rest of APAC, Brazil, Rest of LATAM, Saudi Arabia, UAE, Israel, and Rest of MEA
Thank you for reading our report. Please get in touch with us if you have any query regarding the report or its customization. Our team will ensure the report is best suited to your needs.
About Us:
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Eric Lee
Emergen Research
+91 90210 91709
sales@emergenresearch.com
Visit us on social media:
Facebook
X
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.